Ubamatamab

DRUG10 trials

Sponsors

Regeneron Pharmaceuticals Inc., Asso De Recherche Cancers Gynecologiques, Regeneron Pharmaceuticals, M.D. Anderson Cancer Center, ARCAGY/ GINECO GROUP

Conditions

Advanced/Metastatic Non-Small Cell Lung CancerEndometrial CancerEpithelioid SarcomaFallopian Tube CancerLow-grade Serous Ovarian CancerOvarian CancerPatients with poor prognostic ovarian cancers based on the tumor primary chemonsensitivity and incomplete debulking surgery.Primary Peritoneal Cancer

Phase 1

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

RecruitingNCT03564340

Regeneron PharmaceuticalsEndometrial Cancer, Low-grade Serous Ovarian Cancer, Recurrent Endometrial Cancer +3

Start: 2018-05-21End: 2027-05-10Target: 890Updated: 2026-05-08

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

RecruitingNCT04590326

Regeneron PharmaceuticalsEndometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2020-12-08End: 2027-11-30Target: 612Updated: 2025-11-21

A PHASE 1/2 STUDY OF REGN5668 (MUC16 × CD28, A COSTIMULATORY BISPECIFIC ANTIBODY) ADMINISTERED IN COMBINATION WITH OTHER AGENTS IN MUC16+ MALIGNANCIES

RecruitingCTIS2022-501904-83-00

Regeneron Pharmaceuticals Inc.Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2023-09-11Target: 208Updated: 2025-12-03

A Phase 1/2 Study of REGN4018 (Ubamatamab), a MUC16xCD3 Bispecific Antibody, Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

RecruitingCTIS2024-510783-23-00

Regeneron Pharmaceuticals Inc.Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer +1

Start: 2020-10-29Target: 237Updated: 2025-12-11

REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy.

Not yet recruitingCTIS2025-524232-20-00

Asso De Recherche Cancers GynecologiquesPatients with poor prognostic ovarian cancers based on the tumor primary chemonsensitivity and incomplete debulking surgery.

Target: 43Updated: 2026-06-04

Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer

Not yet recruitingNCT07637851

ARCAGY/ GINECO GROUPOvarian Cancer

Start: 2026-08-01End: 2030-04-01Target: 43Updated: 2026-07-10

Phase 2

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

RecruitingNCT06444880

M.D. Anderson Cancer CenterEpithelioid Sarcoma, Renal Medullary Carcinoma, SMARCB1-Deficient Malignancies

Start: 2024-10-09End: 2028-07-31Target: 40Updated: 2026-06-18

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

RecruitingNCT06787612

Regeneron PharmaceuticalsFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2025-05-28End: 2028-10-30Target: 220Updated: 2026-07-09

A Study to Investigate Ubamatamab With and Without REGN7075 in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

RecruitingNCT07154290

Regeneron PharmaceuticalsAdvanced/Metastatic Non-Small Cell Lung Cancer

Start: 2026-03-18End: 2030-06-24Target: 300Updated: 2026-07-08

Unknown Phase

Compassionate Use of Ubamatamab

Regeneron PharmaceuticalsEpithelioid Sarcoma, Renal Medullary Carcinoma (RMC)

Updated: 2026-03-31

Related Papers

A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.

Journal of Clinical Oncology2026-05-28

A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab in a low-grade serous ovarian cancer cohort: Trial in progress.

Journal of Clinical Oncology2026-05-28

Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes

JCO Precision Oncology2025-08-011 citations

A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.

Journal of Clinical Oncology2024-06-018 citations

First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Journal of Clinical Oncology2023-06-017 citations

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

Journal of Clinical Oncology2021-05-205 citations